

**Scientific Spring Meeting
Friday April 13, 2018**

**Dutch Society for Clinical Pharmacology and Biopharmacy
Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie**

PROGRAMME of the SCIENTIFIC MEETING
Friday April 13, 2018
Vergadercentrum Domstad Utrecht

SCIENTIFIC MEETING OF THE DUTCH SOCIETY FOR CLINICAL PHARMACOLOGY AND BIOPHARMACY (NVKFB)

09.00 h **Welcome & coffee**

ORAL PRESENTATIONS

09.30 h *M.P.J. van Diemen, C.L. Berends, N. Akram, J. Wezel, W.M. Teeuwisse, E.G. Mik, H.E. Kan, A. Webb, J.W. Beenakker, G.J. Groeneveld* (Leiden): Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: a proof-of-pharmacology study

09.45 h *S.M. van den Belt, H.J.L. Heerspink, M. Kirchner, V. Gracchi, D. de Zeeuw, E. Wühl, F. Schaefer* (Groningen): Should RAAS inhibition be discontinued in children with severe chronic kidney disease?

10.00 h *N.M.A. Idzerda, F. Persson, M.J. Pena, B.M. Brenner, P. Brunel, N. Chaturvedi, J.J. McMurray, H.-H. Parving, D. de Zeeuw, H.J. L. Heerspink* (Groningen): NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

- 10.15 h *P. Mian, J.N. van den Anker, K. van Calsteren, P. Annaert, D. Tibboel, M. Pfister, K. Allegaert, A. Dallmann (Leuven): Physiologically-based pharmacokinetic modelling of paracetamol and its metabolites during pregnancy*
- 10.30 h *D. Bury, R. ter Heine, E.M.W. van de Garde, M.R. Nijziel, R.J. Grouls, M.J. Deenen (Eindhoven): A 25% higher vancomycin maintenance dose is required in haematologic patients with neutropenia*
- 10.45 h *D. Bamps, L. Macours, L. Buntinx, J. de Hoon (Leuven): Laser speckle contrast imaging, the future for TRP target engagement biomarker assays*
- 11.00 h **Coffee and Tea Break**
- 11.15 h *S.E. Berends, G.R. D'Haens, K. Bloem, J. Schaap, A. de Vries, T. Rispens, R.A.A. Mathôt (Amsterdam): Clinical feasibility of dried blood samples for infliximab in IBD-patients*
- 11.30 h *L.Binkhorst, A. Sobels, S.S.S. Jankie, P. van der Zee, L.E. Visser, J.A. Portielje (Den Haag): Age-related and sex-related differences in use and toxicity of fluoropyrimidine-oxaliplatin therapy for colon cancer*
- 11.45 h **GENERAL MEETING of the 'NVKFB'**
- 12.50 h **LUNCH**
- 13.30 h **POSTER SESSION**
1. *L.A. Lammers, R. Achterbergh, J.A. Romijn, R.A. Mathôt (Amsterdam): Short-term fasting alters acetaminophen metabolism in humans*
 2. *M.M.M. Wilhelmus, A.B. Smit, M. Loos, B. Drukarch (Amsterdam): Absence of tissue transglutaminase delays amyloid-beta deposition in an Alzheimer's disease mouse model*
 3. *D.J. Brinkman, J. Tichelaar, L.B. Mokkink, T. Christiaens, R. Likic, R. Maciulaitis, J. Costa, E. Sanz, S.R. Maxwell, M.C. Richir, M.A. van Agtmael (Amsterdam): Key learning outcomes for clinical pharmacology and therapeutics education in Europe: A modified Delphi study*

4. *S.M. van den Belt, H.J.L. Heerspink, V. Gracchi, D. de Zeeuw, E. Wühl, F. Schaefer* (Groningen): Early proteinuria lowering by ACE inhibition predicts renal survival in children with chronic kidney disease
5. *S.L. Groenland, R.A.G. van Eerden, R.B. Verheijen, A.D.R. Huitema, R.H.J. Mathijssen, N. Steeghs* (Amsterdam): Increasing pazopanib exposure by splitting intake moments
6. *N.C.B. de Jager, J.M. Heijdra, C.J. Fijnvandraat, F.W.G. Leebeek, M.H. Cnossen, R.A.A. Mathôt for the “OPTI-CLOT” study group* (Amsterdam): Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate[®] P (Humate P) in patients diagnosed with von Willebrand Disease
7. *C.C.J. Dekkers, S. Petrykiv, G. Laverman, D.Z. Cherney, R.T. Gansevoort, H.J.L. Heerspink* (Groningen): Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
8. *M.Y.A.M. Kroonen, T. Sen, G. Laverman, H.J.L. Heerspink* (Groningen): Predictors of albuminuria lowering response to dapagliflozin
9. *M. Nederlof, T.C.G. Egberts, L. van Londen, M.C.F.J. de Rotte, P.C. Souverein, R.C.M. Herings, E.R. Heerdink* (Utrecht): Guideline adherence for laboratory monitoring of ambulatory patients treated with lithium: a retrospective follow-up study in the Netherlands
10. *K.M. Heinhuis, S.G.J.G. In ‘t Veld, G. Dwarshuis, D.A. van den Broek, N. Sol, M.G. Best, T. Wurdinger, N. Steeghs* (Amsterdam): RNA-sequencing of tumor-educated platelets, a novel biomarker for blood-based sarcoma diagnostics
11. *M.A. Sikma, C.C. Hunault, E.M. van Maarseveen, A.D.R. Huitema, E.A. van de Graaf, J.H. Kirkels, M.C. Verhaar, J.C. Grutters, J. Kesecioglu, D.W. de Lange* (Utrecht): Extreme variability of oral tacrolimus pharmacokinetics early after thoracic organ transplantation due to excessive fluctuations in bioavailability (NTR 3912)
12. *S. Wilkes, I. van Berlo, J. ten Oever, F. Jansman, R. ter Heine* (Deventer): A pharmacokinetic justification for continuous dosing of flucloxacillin in non-critically ill patients
13. *B. P.S. Belderbos, S. Bins, R.W.F. van Leeuwen, E. Oomen-de Hoop, N. van der Meer, P. de Bruijn, P. Hamberg, E.N.M. Overkleeft, W.M. van der Deure, M.P. Lolkema, R. de Wit, R.H.J. Mathijssen* (Rotterdam): Influence of enzalutamide on cabazitaxel pharmacokinetics; a drug-drug interaction study in metastatic castration resistant prostate cancer (mCRPC) patients

14. *F.A. Berger, I.H. van der Sijs, N.M.S. de Groot, N.G.M. Hunfeld, J.J.H. Bunge, P.M.L.A. van den Bemt, T. van Gelder* (Rotterdam): Dynamics of the QTc-interval during use of intravenous ciprofloxacin in ICU patients
15. *A.H.M. de Vries Schultink, M.-R.B.S. Crombag, E. van Werkhoven, J.H.M. Schellens, A.D.R. Huitema, J.H. Beijnen* (Amsterdam): Neutropenia and exposure to docetaxel in metastatic castrate-resistant prostate cancer patients compared to other solid tumors: a meta-analysis
16. *W.H. Man, I. Wilting, E.R. Heerdink, G.W.K. Hugenholtz, M.J. ten Berg, W.W. van Solinge, A.C.G. Egberts, E.M. van Maarseveen* (Utrecht): The unbound fraction of clozapine significantly decreases with elevated plasma concentrations of the inflammatory acute phase protein alpha-1-acid glycoprotein
17. *A.M. Punt, N.A. Stienstra, A.C. Egas, R. de Jager, W. Spiering, P. J. Blankestijn, M.L. Bots, E.M. van Maarseveen* (Utrecht): Screening and quantification method for antihypertensive agents using LC-MS/MS: a valuable tool for medication adherence assessment
18. *J.B. Langenhorst, T.P.C. Dorlo, C. van Kesteren, E.M. van Maarseveen, S. Nierkens, C.A. Lindemans, M.A. De Witte, A. van Rhenen, R. Raijmakers, M. Bierings, J. Kuball, J.J. Boelens, A.D.R. Huitema* (Utrecht): Association of fludarabine exposure and survival after allogeneic cell transplantation: retrospectively estimated and prospectively simulated
19. *G.E. Benoist, I.M. van Oort, J.A. Schalken, D.M. Burger, N. Mehra, R. ter Heine, N.P. van Erp* (Nijmegen): Pharmacokinetic and clinical predictors of response to abiraterone in a real world setting
20. *G.E. Benoist, I.M. van Oort, J. Schalken, D.M. Burger, N. Mehra, N.P. van Erp* (Nijmegen): Exposure-toxicity analysis of enzalutamide in patients with metastatic castration resistant prostate cancer
21. *R.E. Wasmann, E.M. Svensson, S.J. Schalkwijk, R.J. Brüggemann, R. ter Heine* (Nijmegen): Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
22. *E. Van Leeuwen, M. Petrovic, M.L. van Driel, A. De Sutter, R. Vander Stichele, T. Declercq, T. Christiaens* (Gent): Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.
23. *C.J.T. van der Togt, T.S. Sprong, H.W. Fleuren, C. Kramers* (Nijmegen): Evaluation of a continuous infusion protocol for vancomycin: checking protocol adherence and efficacy

24. *R.E. Wasmann, C. Smit, R. ter Heine, A. Colbers, H.P.A. van Dongen, E.J. Hazebroek, D.M. Burger, C.A.J. Knibbe, R.J.M. Brüggemann* (Nijmegen): Micafungin pharmacokinetics and probability of target attainment in obese individuals
25. *M. Saghari, P. Gal, M.L. de Kam, M.B.A. van Doorn, J. Burggraaf, M. Moerland, R. Rissmann* (Leiden): Antera 3D and laser speckle contrast imaging as novel tools to characterize type IV hypersensitivity skin response in healthy volunteers
26. *L. Martial, J. Kerkhoff, N. Martinez, M. Rodríguez, R. Coronel, G. Molinas, M. Roman, R. Gomez, S. Aguirre, E. Jongedijk, J. Huisman, D. Touw, D. Pérez, G. Chaparro, F. Gonzalez, R. Aarnoutse, J.-W. Alffenaar, C. Magis-Escurra* (Nijmegen): Validation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children
27. *M.T.J. van Bussel, D. Pluim, B. Milojkovic Kerklaan, J.H. Beijnen, J.H.M. Schellens, D. Brandsma* (Amsterdam): Circulating tumor cells analysis in cerebrospinal fluid in patients with epithelial tumors with suspected leptomeningeal metastasis
28. *J.J.J. Geenen, G.M.H.E. Dackus, Ph.C. Schouten, S. Marchetti, H. van Tinteren, J.H. Beijnen, G.S. Sonke, S.C. Linn, J.H. Schellens* (Amsterdam): The REVIVAL study: a phase I trial to determine the maximum tolerable dose (MTD) of two cycles olaparib-carboplatin followed by olaparib monotherapy in patients with advanced cancer
29. *S.E.M. Vonk, C.J. Majoor, E.J.M. Weersink, E.M. Kemper for the Amsterdam CF research group* (Amsterdam): Tobramycin and vestibulotoxicity: 4 cases
30. *M.E. Cloesmeijer, E.H.J. Krekels, A.M. Lynn, A. Smits, D. Tibboel, Y. Daali, K.T. Olkkola, K. Allegaert, P. Mian* (Leiden): Population pharmacokinetics of enantiomer specific intravenous ketorolac across the human-age span
31. *P. Mian, M.J. van Esdonk, K.T. Olkkola, B.C.M. de Winter, A. Liukas, I. Spriet, D. Tibboel, M. Petrovic, B.C.P. Koch, K. Allegaert* (Rotterdam): Setting the stage for evidence-based model-informed dosing of intravenous paracetamol in older people
32. *D. Pluim, W. Ros, M.T.J. van Bussel, D. Brandsma, J.H. Beijnen, J.H.M. Schellens* (Amsterdam): Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid
33. *J.M. Janssen, G.J.L. Kaspers, D. Niewerth, A.J. Wilhelm, C.M. Zwaan, J.H. Beijnen, A.D.R. Huitema* (Amsterdam): Semi-physiological pharmacokinetics of bortezomib in pediatric patients with acute lymphoblastic leukemia

34. *N.A.G. Lankheet, K.R.M. Ferrier, F.G. Jansman, S.E. Gibbons, J.L.M. Martin, K. McAllister, S.H. Khoo, D.M. Burger, N.P. van Erp* (Nijmegen): Development of an online drug-drug interaction resource to support safe prescription of oncolytics
35. *G. Van Lancker, E. Van Bever, B. Delafontaine, M. Azermai, K. Boussery, E.L. Swart, A. Chahbouni, J. Van Bocxlaer, L. Van Bortel, P. Colin* (Gent): Switchability of gabapentin formulations: assessment of bioequivalence between Neurontin® and Gabasandoz® on the individual patient level
36. *K. Eechoute, R.H.J. Mathijssen, T. van Gelder* (Rotterdam): Tamoxifen-induced fatty liver disease in a Caucasian patient
37. *J. Roosendaal, H. Rosing, L. Lucas, A. Oganessian, J.H.M. Schellens, J.H. Beijnen* (Amsterdam): Development and validation of an LC-MS/MS assay for the quantification of intracellular decitabine nucleotides and genomic DNA incorporated decitabine in peripheral blood mononuclear cells and whole blood
38. *E.B. Uitvlugt, M.J.A. Janssen, E.L. Kneepkens, B.J.F. van den Bemt, P.M.L.A. van den Bemt, F. Karapinar-Çarkıt* (Amsterdam): Which part of unplanned hospital readmissions within 30 days after discharge is medication related? A study to assess the percentage and potential preventability and causes
39. *D. Damoiseaux, A. Lalmohamed, M. de Witte, N.K.A. van Eijkelenburg, K. de Kanter, E.M. van Maarseveen* (Utrecht): Switching to a methotrexate immuno-assay with higher specificity compared to its predecessor results in a shorter time period to reach target concentrations
40. *M. El Amrani, C.L. Szanto, C.E. Hack, A.D.R. Huitema, S. Nierkens, E.M. van Maarseveen* (Utrecht): Quantification of total dinutuximab concentrations with liquid chromatography tandem mass-spectrometry
41. *C. Bastida, D. Soy, V. Ruíz, R. Sanmartí, M. Pascal, J. Yagüe, A.D.R. Huitema* (Amsterdam): Different dynamics of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment
42. *M.A.G.M. Kroon, J.K. Berbee, S. Majait, E.L. Swart, H.W.M. van Laarhoven, O. van Tellingen, E.M. Kemper* (Amsterdam): Plasma concentration of curcumin and its metabolites in subjects using over the counter supplements in daily life is low
43. *A.M. Harmsze, C. de Jong, I. Drubbel, G.A.M. Roelfs, E.L. Swart* (Nieuwegein): Clomipramine toxicity in a CYP2D6 poor metabolizer who suddenly stopped smoking

44. *A. Keyany, J.T.H. Nielen, P.C. Souverein, F. de Vries, B. van den Bemt* (Nijmegen): Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: a case-control study
45. *S.A.W. van Moorsel, A.A. van Bodegraven, D.R. Wong* (Sittard): Therapeutic drug monitoring at week 1 and prediction of clinical sustainability of thiopurines in IBD-patients
46. *R. Achterbergh, L.A. Lammers, R.A. Mathôt, J.A. Romijn* (Amsterdam): A short-term high fat increases exposure to acetaminophen metabolites that are related to hepatotoxicity
47. *S. van Oort, F. Rutters, M. van Herwaarden, P. Elders, K. Kramers, on behalf of the Diabetes Pearl from the Chain of Pearls Initiative* (Amsterdam): The characterization of people with type 2 diabetes mellitus and polypharmacy in the Netherlands: The Diabetes Pearl Cohort
48. *S. Crutzen, K. Taxis, P. Denig, on behalf of the ESOM project group* (Groningen): Efficient selection of older patients for medication review: development and validation of a selection algorithm
49. *M.J. Bakkum, J. Tichelaar, A. Wellink, M.C. Richir, M.A. van Agtmael* (Amsterdam): Digital learning to improve prescribing practice: a systematic review
50. *M. Reumerman, J. Tichelaar, R. van Eekeren, M.C. Richir, M.A. van Agtmael* (Amsterdam): Long term and clinical effects of an pharmacovigilance educational intervention in specialist oncology nurses
51. *M. Sjak Shie, A. Sobels, P. de Wolf, L. Binkhorst* (Den Haag): Drug interactions between tyrosine kinase inhibitors and St. John's wort unnoticed in clinical practice
52. *H.A. Crommelin, A.D.M. Vorselaars, C.H.M. van Moorsel, J.H. Proost, J.C. Grutters, V.H.M Deneer* (Nieuwegein): Pharmacokinetics and exposure-response relationship of infliximab in severe sarcoidosis
53. *R.A. Wijma, A. Huttner, S. Harbarth, R.J.M. Brüggemann, J.W. Mouton, A.E. Muller* (Rotterdam): The pharmacokinetics of nitrofurantoin in healthy volunteers using two frequently used dosing regimen

- 14.15 h Lecture of the winner of the ‘**NVKFB**’-**Thesis Award 2017 (1)**
- 14.35h Lecture of the winner of the ‘**NVKFB**’-**Thesis Award 2017 (2)**
- 14.55 h Lecture of the winner of the ‘**NVKFB**’-**TOP Publication Award 2017**
- 15.10 h Lecture of the winner of the ‘**NVKFB**’-**Education Award 2017**
- 15.25 h **Coffee and Tea Break**

ORAL PRESENTATIONS

- 15.45 h *M.-R.B.S. Crombag, A.H.M. de Vries Schultink, S.L.W. Koolen, M. Joerger, J.H.M. Schellens, N.P. van Erp, R.H.J. Mathijssen, J.H. Beijnen, A.D.R. Huitema* (Amsterdam): Older age has minor impact on paclitaxel exposure: a population pharmacokinetic model
- 16.00 h *A. Sobels, J. Bongers, E.M. Westerman* (Den Haag): The introduction of biosimilar rituximab in clinical practice
- 16.15 h *L.A. Lammers, R. Achterbergh, J.A. Romijn, R.A. Mathôt* (Amsterdam): Effect of short-term fasting and high fat diet on midazolam metabolism
- 16.30 h *L.M.A. Favié, F. Groenendaal, C.M.A. Rademaker, T.R. de Haan, T.C.G. Egberts, F. van Bel, M.P.H. van den Broek, A.D.R. Huitema, and the PharmaCool Study Group* (Utrecht): Pharmacokinetics of morphine and its metabolites in neonates with hypoxic-ischemic encephalopathy during and after therapeutic hypothermia
- 16.45 h Closure**